

# Cardiac Involvement of Hepatitis B and C Virus Infection

MOHAMMAD SAIFULLAH PATWARY<sup>1</sup>, KMHS SIRAJUL HAQUE<sup>2</sup>, NUSRAT SHOAIB<sup>3</sup>, KHONDAKER SYEDUS SALEHIN<sup>4</sup>, ATM IQBAL HOSAN<sup>5</sup>

<sup>1</sup>Dept. of Medicine & Cardiology, Marks Medical College, <sup>2</sup>Professor & Head, Dept. of Cardiology, Anwer Khan Modern Medical College, <sup>3</sup>Dept. of Community Medicine, H F R C Medical College, <sup>4</sup>Postgraduate fellow in Cardiology, Canterberry Christ Church University, UK, <sup>5</sup>Department of Cardiology, Bangabandhu Sheikh Mujib Medical University, Dhaka

**Address for Correspondence:** Dr.Mohammad Saifullah Patwary, Professor(c.c), Dept. of Medicine & Cardiology, Marks Medical College, Mirpur-14, Dhaka, E-mail : dr\_saif71@yahoo.co.uk

## Abstract

*Hepatitis B virus (HBV) and Hepatitis C virus (HCV) are the cause of many different forms of heart disease worldwide and yet few cardiologists are aware of it as an etiology of heart disease, or its treatment. The burden of HBV and HCV derived heart diseases are global, with a higher prevalence in Asia, Africa, and low- and middle-income countries. The study showed that in more than 10% of Japanese patients, their cardiomyopathies are associated with HCV infection. More recently, it is found in the USA that up to 15% of patients with heart failure with myocarditis have been associated HCV infection. In contrast, in China 79% of patients with hepatocellular cancer and 37% of hepatitis C patients have heart disease, as detected by measuring a proven and sensitive biomarker of heart disease, NT-proBNP. In Pakistan, 17% of hepatitis C patients have heart diseases, as measured by this metric (NT-proBNP). Based on these data, 3% of 6.6 billion (198 million) persons worldwide are infected with HCV and 17–37% (34–73 million) persons are suffering from HCV-derived heart diseases. These figures may be comparable to the number of patients with hepatitis C. HCV infection causes only hepatitis in some patients, only heart diseases in some patients, and both hepatitis and heart diseases in other patients. A global network is required to establish methods to detect heart diseases caused by infectious agents. Other goals for the network are the expansion of preventive and therapeutic programs in under privileged countries.*

**Keywords :** *Cardiomyopathy; Heart failure; Myocarditis; Virus; Hepatitis B, Hepatitis C*

## Introduction:

Congestive Heart failure is one of the common clinical conditions encountered in medical practice. Heart failure is rapidly evolving to be a worldwide epidemic. Although most of the adverse outcomes related to cardiovascular diseases have been improving, the only exception is heart failure. As survival for acute cardiac catastrophic events such as myocardial infarction and sudden deaths improves, increasing number of patients suffer from heart failure. There are about 23 million people with heart failure in the world, 5 million in the United States, and 550 thousand new cases are added in 2003<sup>1</sup>. Meta analysis of 21 studies (n = 37,791) with mild to moderate heart failure showed the prevalence of ischemic heart failure is 24–83% (average 64%)<sup>2</sup>. In contrast, dilated cardiomyopathy is considered 63% of all causes of heart failure. In patients with severe heart failure who were candidates for heart transplantation, about one half had ischemic heart failure and one-half had dilated cardiomyopathy in Western countries. Therefore, dilated cardiomyopathy is the major cause of severe heart failure.

## New classification of cardiomyopathies


In 1968, the World Health Organization (WHO) defined cardiomyopathy as a heart muscle disease of unknown etiologies in which the dominant feature is cardiomegaly and cardiac failure; excluded are myocardial dysfunction due to coronary, systemic or pulmonary vascular disease. Distinction was made between secondary cardiomyopathies, in which the heart muscle disease was associated with a known single cause, systemic disease or syndrome, and primary cardiomyopathy, in which the heart muscle disease was of unknown etiology. In 1980, the WHO, jointly with the International Society and Federation of Cardiology, chose to limit the term Cardiomyopathy to heart muscle disease of unknown etiology. The updated WHO definition in 1995 was “diseases of myocardium associated with cardiac dysfunction” and was included for the first time newly recognized Arrhythmogenic Right Ventricular Cardiomyopathy / Dysplasia (ARVC/D) and primary restrictive cardiomyopathy<sup>3-7</sup>.

In 2006, the AHA expert consensus panel proposed the definition: Cardiomyopathies are a heterogeneous group

of diseases of the myocardium associated with mechanical and/or electrical dysfunction that usually but not invariably exhibit inappropriate ventricular hypertrophy or dilatation and are due to a variety of causes that frequently genetic<sup>8</sup>. Cardiomyopathies thus are confined to the heart or are part of a generalized systemic disorder, often leading to cardiovascular death or progressive heart failure with related disability. Cardiomyopathies were divided into two major groups based on predominant organ involvement. Primary cardiomyopathies are genetic, nongenetic, acquired and those solely or predominantly confined to heart muscle and are relatively few in number. Secondary cardiomyopathies show pathological myocardial involvement as part of a large number of generalized systemic (multi-organ) disorders. The panel recommended that cardiomyopathies can be most effectively classified as primary : genetic; mixed (genetic and nongenetic), acquired; and secondary<sup>8</sup> [Table-1]. Recently, the European Society of Cardiology working group on myocardial and pericardial diseases defined, “Cardiomyopathy as a myocardial disorder in which the heart muscle is structurally and functionally abnormal, in the absence of coronary artery disease, hypertension, valvular diseases, and congenital heart disease.” Cardiomyopathies were grouped into specific morphological and functional phenotypes; each phenotype was then sub-classified into familial and non-familial forms<sup>9</sup> [Table-1]. About one-half of hypertrophic Cardiomyopathy occurs familiarly, and one-half of those patients are associated with gene mutations. Confusion arises when in some cases of non-familial hypertrophic Cardiomyopathy, gene mutation are not seen, on the other hand some of the dilated Cardiomyopathy showed gene mutation of hypertrophic Cardiomyopathy. Although myocarditis is believed to be the major cause of dilated cardiomyopathy, myocarditis is often associated with hypertrophic cardiomyopathy which is caused by a viral infection such as hepatitis C virus<sup>10-13</sup>, Hepatitis B & C virus infection are important causes of hepatitis both in developed & developing country. In Bangladesh Islam MN, Islam KM, Islam N et al, reported HBs positive in 27.2% of adult & 15.4% of children with acute hepatitis, 60% of post transfusion hepatitis patient & 65.5% of doctor. Selimur Rahman et al reported 31.25% cases of acute hepatitis, 76.3% of chronic hepatitis. In a study Hasan Ashraf et al among 1997 participants 452 (22.6%) for anti-HBc and 116 (5.8%) for both HBsAg and anti HBc or by cardiac sarcoidosis as discussed below<sup>14</sup>. Therefore, one etiology is not consistent with one phenotype of cardiomyopathy. Because the therapy should be based on the etiology, there will be proposed a new classification of cardiomyopathies (Table-2). For example, when compared with the WHO classification, dilated cardiomyopathy is classified into infectious, genetic, and so forth for etiology, left or right

ventricle for anatomy, and systolic dysfunction for physiology. Hypertrophic Cardiomyopathy with obstruction is classified into genetic, infectious etc for etiology, septal hypertrophy for anatomy, and diastolic failure for physiology<sup>10-14</sup>.

**Table-I**  
*Classification or grouping of Cardiomyopathy<sup>8, 9</sup>*



**Table-II**  
*A new classification of cardiomyopathies<sup>8, 9</sup>*

I. Etiological classification	A. Genetic B. Infectious C. Nutritional D. Unknown
II. Anatomical (structural) classification	A. Dilated a. LV b. RV B. Hypertrophic a. Septum b. Diffuse c. Free wall d. Apex
III. Physiological (mechanical) classification	A. Systolic failure/dysfunction B. Diastolic failure/dysfunction C. Both
IV. Electrical classification	A. Ion channel disorders B. Conduction system disease C. Others

### Comparison of classifications of cardiomyopathies WHO/ISFC classification Proposed classification<sup>8,9</sup>

DCM (with viral infection)	I B, II A a, III A
DCM (with gene mutation)	IA, II A a, III A
HCM (with gene mutation outflow obstruction)	I A, II B a, III B
Apical HCM (with unknown cause)	I D, II B d, III B
Apical HCM (with HCV infection)	I B, II B d, III B
ARVC/D (with gene mutation)	IA, II A b, III B
ARVC/D (with HCV infection)	I B, II A b, III B
Long QT syndrome	I A, IV A

### Role of viruses in the pathogenesis of cardiomyopathies

Myocarditis is one of the cardiological problem encounter in clinical practice, it is caused by many viruses and also it may represent as a part of many systemic diseases. Myocarditis is thought to be most commonly caused by enteroviruses, particularly coxsackievirus B. However, in many cases, when myocarditis has been diagnosed on the basis of clinical characteristics, no definite confirmation of viral origin is obtained, despite extensive laboratory investigations. The evidence is often only circumstantial, and a direct, conclusive proof of cardiac involvement is not available. However, accumulating evidence links viral myocarditis with the eventual development of dilated cardiomyopathy<sup>18-20</sup>. Affection of the heart is manifested on the variety of pathological lesions e.g. when myocardial necrosis occurs diffusely, congestive heart failure develops and later dilated cardiomyopathy. If myocardial lesions are localized, a ventricular aneurysm may form. When complicated with arrhythmias, myocarditis presents as arrhythmogenic right ventricular Cardiomyopathy<sup>21</sup>. When myocardial necrosis is localized to the subendocardium, restrictive Cardiomyopathy may develop<sup>21</sup>. While it has not been established that hypertrophic cardiomyopathy may be a complication of viral myocarditis, asymmetrical septal hypertrophy has in fact, sometimes been observed in patients with myocarditis<sup>22</sup>. Hepatitis B antibody was detected in 8.6% of dilated cardiomyopathy and 14.6% of hypertrophic cardiomyopathy patients. Hepatitis C antibody was present in 6.7% of dilated cardiomyopathy and 9.5% of hypertrophic cardiomyopathy patients<sup>17</sup>. Recently the importance of hepatitis C virus (HCV) has been noted in patients with hypertrophic cardiomyopathy, dilated cardiomyopathy, and myocarditis<sup>10-13, 23, 24</sup>.

### Burden of cardiomyopathies: incidence and prevalence

There are few epidemiologic data of myocarditis. The Japanese Scientists conducted nationwide epidemiological surveys of cardiomyopathies in Japan<sup>14-16</sup>.

Disorders surveyed included idiopathic dilated Cardiomyopathy (DCM), hypertrophic cardiomyopathy (HCM), restrictive cardiomyopathy (RCM), ARVC/D, mitochondrial disease, Fabry's disease of the heart, and prolonged Q-T interval syndrome. The Scientist estimated that 17,700 persons had dilated Cardiomyopathy (14 per 100,000), 21,900 had hypertrophic cardiomyopathy, 300 had restrictive cardiomyopathy, 520 had ARVD, 640 had mitochondrial disease, 150 had Fabry's disease of the heart, and 1000 had prolonged Q-T interval syndrome. The prevalence of both dilated cardiomyopathy and hypertrophic cardiomyopathy was higher in men than women, the men to women ratios were 2.6 and 2.3; for dilated cardiomyopathy and hypertrophic cardiomyopathy respectively. Detailed data on patients with dilated cardiomyopathy or hypertrophic Cardiomyopathy were collected by a follow-up survey. In one year, more patients with dilated Cardiomyopathy (5.6%) died than with hypertrophic Cardiomyopathy (2.8%). Congestive heart failure and arrhythmias were the leading causes of death for dilated cardiomyopathy and hypertrophic cardiomyopathy respectively. Among patients with dilated Cardiomyopathy (n = 506) and hypertrophic Cardiomyopathy (n = 330) who had myocardial biopsies, significant mononuclear cell infiltrations were seen in 24% with dilated cardiomyopathy and 15% with hypertrophic cardiomyopathy suggesting the presence of inflammation in these patients. Cardiac troponin T was increased in 3% of dilated Cardiomyopathy and 9% of hypertrophic cardiomyopathy patients. Hepatitis B antibody was detected in 8.6% of dilated cardiomyopathy and 14.6% of hypertrophic cardiomyopathy patients. Hepatitis C antibody was present in 6.7% of dilated cardiomyopathy and 9.5% of hypertrophic cardiomyopathy patients. These data suggested that hepatitis B and C virus may cause myocarditis and cardiomyopathies. Five variables, left ventricular dilatation, lower left ventricular ejection fraction, higher NYHA functional class, older age, and male sex were independently related to poor prognosis<sup>17</sup>.

### Phenotypes of HCV cardiomyopathies

In an initial study, Japanese Scientist found HCV RNA by polymerase chain reaction in the hearts of 19% of patients with dilated cardiomyopathy<sup>24</sup>. Over a 10-year period, they identified 9.9% of patients with dilated cardiomyopathy had evidence of HCV infection, in contrast to only 2.5% of patients with ischemic heart disease. The main clinical manifestations at initial

presentation were heart failure and cardiac arrhythmias. Positive and negative strands of HCV RNA were detected in the hearts of patients by Matsumori<sup>23</sup>. Because negative RNA molecules are intermediates in the replication of the HCV genome, the Scientist presume that HCV replicates in myocardial tissues. During the same period, identified 14.1% of patients with hypertrophic cardiomyopathy had evidence of HCV infection. None of these patients had a family history of hypertrophic cardiomyopathy. Apical hypertrophic cardiomyopathy was diagnosed in 8% of patients who had ace of spade-shaped deformities of the left ventricle. Histopathologic studies showed mild to severe degrees of myocyte hypertrophy in the right or left ventricle, mild to moderate fibrosis, and mild cellular infiltration. Positive and negative strands of hepatitis C virus RNA were found in the biopsied hearts of patients<sup>25</sup>. Teragaki and coworkers<sup>26</sup> recently found 18 of 80 Japanese patients with hypertrophic cardiomyopathy (22.5%) had positive HCV antibodies, a prevalence significantly higher than in controls.

#### **Prolonged persistence of hepatitis C virus genomes in paraffin-embedded hearts**

A multicenter study by the Scientific Council on Cardiomyopathies of the World Heart Federation (Bernhard Maisch, MD, Chairman) showed HCV genomes in 18% of patients with dilated Cardiomyopathy and myocarditis from Italy, and in 36% from the United States, two from patients with myocarditis and two with ARVC<sup>25</sup>, which suggests that HCV may cause ARVC. In collaboration with the National Cardiovascular Center and Juntendo University, they have detected HCV RNA in paraffin sections of autopsied hearts from 26% of patients with hypertrophic cardiomyopathy, 12% of patients with dilated cardiomyopathy, and 33% of patients with myocarditis<sup>13</sup>. They also examined autopsied hearts from patients with dilated cardiomyopathy in a collaborative study with the University of Utah and found HCV RNA in 35% of hearts. The sequences of HCV genomes recovered from these hearts were highly homologous to the standard strain of HCV<sup>25</sup>. However, the rates of HCV genomes detection in the hearts of patients with cardiomyopathies varied widely among different regions of the world. For example, no HCV genome was detected in hearts obtained from St. Paul's Hospital, in Vancouver, Canada. These observations suggest that the frequency of cardiomyopathy caused by HCV infection may be different in different regions or different populations. They analyzed sera stored during

the US Myocarditis Treatment Trial<sup>27</sup> of immunosuppression in patients with heart failure and myocarditis. Anti-HCV antibodies were identified in 4.4% of patients, including 5.9% of patients with biopsy-proven myocarditis. According to the US Centers for Disease Control, the prevalence of HCV infection in the general US population is 1.8%<sup>28</sup>, thus HCV infection is more prevalent in patients with heart failure because of myocarditis. Furthermore, variations between 0% and 15% were found in the prevalence of HCV infection among the different medical centers and regions<sup>29</sup>.

#### **Genes responsible for development of different phenotypes of HCV cardiomyopathies**

The major human histocompatibility complex (MHC) is located on the short arm of chromosome 6 and encodes for several protein products involved in immune function, including complement, TNF- $\alpha$ , and the human leukocyte antigen (HLA) complex, the polymorphisms of which are often proposed as determinants for the susceptibility to various diseases. Recent studies of HCV hepatitis showed that DQB1\*0301 was associated with clearance of the virus. DRB1\*1101, which is also in linkage disequilibrium with DQB1\*0301, was associated with clearance. Several other studies have examined the association of MHC alleles with the progression of liver disease, and DQB1\*0401 and DRB1\*0405 were more prevalent among patients who developed chronic liver disease. The Scientist found that DPB1\*0401 and DPB1\*0901 were significantly associated with an increased risk of HCV-hypertrophic cardiomyopathy in the dominant model. The disparity in the gene-dose effect of two susceptible DPB1 alleles may be attributable to the difference between the susceptible and resistant residue-combination consisting of the DPb anchor pocket for antigenic peptide-binding. These results implied that the HLA-DP molecules with a specificity pocket appropriate for an HCV antigen(s) might confer the progressive process of hypertrophic Cardiomyopathy in HCV-infected individuals<sup>30</sup>. In addition, no significant association was found between the MHC markers and HCV-hypertrophic cardiomyopathy. This marked difference in the MHC-related disease susceptibility for HCV-associated cardiomyopathy strongly suggests that the development of HCV-dilated cardiomyopathy and HCV-hypertrophic cardiomyopathy is under the control of different pathogenic mechanisms<sup>31</sup>.

#### **Treatment of HCV cardiomyopathies**

In patients with HCV hepatitis, the success of treatment can be measured by the biochemical and virologic

responses. However, therapeutic markers have not been introduced in clinical practice to follow HCV cardiomyopathies. The Scientist have examined the effects of interferon on myocardial injury associated with active HCV hepatitis in collaboration with Shimane University<sup>32</sup>. They used TL-201-SPECT imaging, because it is more sensitive than electrocardiography or echocardiography to detect myocardial injury induced by HCV. The SPECT scores decreased in 8 of 15 patients (53%) in whom interferon treatment was completed. Circulating HCV disappeared after interferon therapy in all patients who had either a decrease or no change in SPECT scores, and HCV genomes persisted in the blood of two patients whose clinical status worsened<sup>32</sup>. This preliminary study suggests that interferon is a promising treatment for myocardial disease caused by HCV. They have also reported beneficial treatment with interferon guided by serial measurement of serum HCV RNA and cardiac troponin T in a patient presenting with dilated cardiomyopathy and striated myopathy attributable to HCV infection<sup>33</sup>.

#### Impact of HCV on vascular disease

There are several reports on the association of diabetes mellitus and HCV infection. Also, HCV infection has been reported as a risk factor of atherosclerosis<sup>39, 40</sup>. Therefore, it is important to clarify the role of HCV infection as a risk factor of atherosclerosis and vascular diseases, especially in the geographic areas with a high prevalence of HCV infection. The anti-viral treatment may cure the diseases, and decrease the number of patients. Thus, the cost to treat these patients and importantly, the burden of disease to the patients can be decreased<sup>39-42</sup>.

#### Conclusion:

In Bangladesh, we are not very aware of Hepatitis virus induced heart disease. Some personal communication reveal that Hepatitis positive case are reported with heart failure. No proven strategy has been identified to reduce the numbers of patients living with, and dying from, cardiomyopathies and myocarditis due to infectious agents. Yet, the morbidity and mortality are high. We can treat these diseases by anti-viral agents, and some patients with cardiomyopathies and heart failure may be cured. Thus, treating these persons much earlier in the disease process—because of the ability to identify and treat HCV infection—will reduce the burden of cardiomyopathies and heart failure in patients and reduce the costs of treatment of these complex and long-term diseases.

#### References:

1. Thom T, Haase N, Rosamond W, Howard VJ, Rumsfeld J, Manolio T, Zheng ZJ, Flegal K, O'Donnell C, Kittner S, Lloyd-Jones D, Goff DC, Jr., Hong Y, Adams R, Friday G, Furie K, Gorelick P, Kissela B, Marler J, Meigs J, Roger V, Sidney S, Sorlie P, Steinberger J, Wasserthiel-Smoller S, Wilson M, Wolf P. Heart disease and stroke statistics—2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. *Circulation*. 2006;113:e85–e151.
2. Gheorghide M, Bonow R. Heart failure as a consequence of arteriosclerotic coronary artery disease. In: Mann D, editor. *Heart failure*. Philadelphia, USA: Saunders; 2004, 351–62.
3. The EPOCH Study Group, Effects of pimobendan on adverse cardiac events and physical activities in patients with mild to moderate chronic heart failure: the effects of pimobendan on chronic heart failure study (EPOCH study). *Circ J* 2002;66:149–57.
4. Hori M, Sasayama S, Kitabatake A, Toyo-oka T, Handa S, Yokoyama M, Matsuzaki M, Takeshita A, Origasa H, Matsui K, Hosoda S. Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure: the Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial. *Am Heart J* 2004;147:324–30.
5. Matsumori A. Efficacy and safety of oral candesartan cilexetil in patients with congestive heart failure. *Eur J Heart Fail* 2003;5: 669–77.
6. Nishigaki K. Indication of recipients for cardiac transplant. *Today's Transplant* 2005;18:294–301.
7. Richardson P, McKenna W, Bristow M, Maisch B, Mautner B, O'Connell J, Olsen E, Thiene G, Goodwin J, Gyarfas I, Martin I, Nordet P. Report of the 1995 World Health Organization / International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. *Circulation* 1996;93:841–2.
8. Maron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D, Arnett D, Moss AJ, Seidman CE, Young JB. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. *Circulation* 2006;113:1807–16.
9. Elliott P, Andersson B, Arbustini E, Bilinska Z, Cecchi F, Charron P, Dubourg O, Kuhl U, Maisch B, McKenna WJ, Monserrat L, Pankuweit S, Rapezzi C, Seferovic P, Tavazzi L, Keren A. Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. *Eur Heart J* 2008;29:270–6.
10. Matsumori A. Hepatitis C virus infection and cardiomyopathies. *Circ Res* 2005;96:144–7.
11. Matsumori A, Matoba Y, Nishio R, Shioi T, Ono K, Sasayama S. Detection of hepatitis C virus RNA from the heart of patients with hypertrophic cardiomyopathy. *Biochem Biophys Res Commun* 1996;222:678–82.
12. Matsumori A, Ohashi N, Nishio R, Kakio T, Hara M, Furukawa Y, Ono K, Shioi T, Hasegawa K, Sasayama S. Apical hypertrophic

- cardiomyopathy and hepatitis C virus infection. *Jpn Circ J* 1999;63:433–8.
13. Matsumori A, Yutani C, Ikeda Y, Kawai S, Sasayama S. Hepatitis C virus from the hearts of patients with myocarditis and cardiomyopathy. *Lab Invest* 2000;80:1137–42.
  14. Matsumori A, Hara M, Nagai S, Izumi T, Ohashi N, Ono K, Sasayama S. Hypertrophic cardiomyopathy as a manifestation of cardiac sarcoidosis. *Jpn Circ J* 2000;64: 679–83.
  15. Matsumori A, Furukawa Y, Hasegawa K, Sato Y, Nakagawa H, Morikawa Y, Miura K, Ohno Y, Tamakoshi A, Inaba Y, Sasayama S. Epidemiologic and clinical characteristics of cardiomyopathies in Japan: results from nationwide surveys. *Circ J* 2002;66:323–36.
  16. Miura K, Nakagawa H, Morikawa Y, Sasayama S, Matsumori A, Hasegawa K, Ohno Y, Tamakoshi A, Kawamura T, Inaba Y. Epidemiology of idiopathic cardiomyopathy in Japan: results from a nationwide survey. *Heart* 2002;87:126–30.
  17. Miura K, Matsumori A, Nasermoaddeli A, Soyama Y, Morikawa Y, Sakurai M, Kitabatake A, Nagai M, Inaba Y, Nakagawa H. Prognosis and prognostic factors in patients with idiopathic dilated cardiomyopathy in Japan. *Circ J* 2008;72:343–8.
  18. Liu PP, Mason JW. Advances in the understanding of myocarditis. *Circulation* 2001;104:1076–82.
  19. Matsumori A, Kawai C. An animal model of congestive (dilated) cardiomyopathy: dilatation and hypertrophy of the heart in the chronic stage in DBA/2 mice with myocarditis caused by encephalomyocarditis virus. *Circulation* 1982;66:355–60.
  20. Matsumori A, Kawai C. An experimental model for congestive heart failure after encephalomyocarditis virus myocarditis in mice. *Circulation* 1982;65:1230–5.
  21. Matsumori A. Animal models: pathological findings and therapeutic considerations. In: Banatvala J, Edward A, editors. *Viral infection of the heart*. London; 1993. p. 110–37.
  22. Kawano H, Kawai S, Nishijo T, Shirai T, Inagaki Y, Okada R. An autopsy case of hypertrophic cardiomyopathy with pathological findings suggesting chronic myocarditis. *Jpn Heart J* 1994;35:95–105.
  23. Matsumori A. Introductory chapter. In: Matsumori A, editor. *Cardiomyopathies and heart failure. Biomolecular infectious and immune mechanisms*. Boston: Kluwer Academic Publisher; 2003. p. 1–15.
  24. Matsumori A, Matoba Y, Sasayama S. Dilated Cardiomyopathy associated with hepatitis C virus infection. *Circulation* 1995;92: 2519–25.
  25. Matsumori A. Role of hepatitis C virus in myocarditis and cardiomyopathies. *J Geriatr Cardiol* 2004;1:83–9.
  26. Teragaki M, Nishiguchi S, Takeuchi K, Yoshiyama M, Akioka K, Yoshikawa J. Prevalence of hepatitis C virus infection among patients with hypertrophic cardiomyopathy. *Heart Vessels* 2003;18:167–70.
  27. Mason JW, O'Connell JB, Herskowitz A, Rose NR, McManus BM, Billingham ME, Moon TE. A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. *N Engl J Med* 1995;333:269–75.
  28. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, Kaslow RA, Margolis HS. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. *N Engl J Med* 1999;341:556–62.
  29. Matsumori A, Shimada T, Chapman NM, Tracy SM, Mason JW. Myocarditis and heart failure associated with hepatitis C virus infection. *J Card Fail* 2006;12:293–8.
  30. Shichi D, Matsumori A, Naruse TK, Inoko H, Kimura A. HLA-DPbeta chain may confer the susceptibility to hepatitis C virus-associated hypertrophic cardiomyopathy. *Int J Immunogenet* 2008;35:37–43.
  31. Shichi D, Kikkawa EF, Ota M, Katsuyama Y, Kimura A, Matsumori A, Kulski JK, Naruse TK, Inoko H. The haplotypeblock, NFKBIL1-ATP6V1G2-BAT1-MICB-MICA, within the class III-class I boundary region of the human major histocompatibility complex may control susceptibility to hepatitis C virus-associated dilated cardiomyopathy. *Tissue Antigens* 2005;66:200–8.
  32. Ooyake N, Kuzuo H, Hirano Y, Shimada T, Matsumori A. Myocardial injury induced by hepatitis C virus and interferon therapy [Abstract]. *J Jpn Soc Int Med* 1999;88(suppl.):241.
  33. Sato Y, Takatsu Y, Yamada T, Kataoka K, Taniguchi R, Mimura R, Sasayama S, Matsumori A. Interferon treatment for dilated cardiomyopathy and striated myopathy associated with hepatitis C virus infection based on serial measurements of serum concentrations of cardiac troponin T. *Jpn Circ J* 2000;64:321–4.
  34. Crabb C. Infectious diseases. Hard-won advances spark excitement about hepatitis C. *Science* 2001;294:506–7.
  35. Wang L, Li Y, Li T, Zhuang H, Matsumori A. The association of increased concentration of NT-proBNP with hepatitis viruses infection [Abstract]. In: *The first international congress of cardiomyopathies and myocarditis*. Kyoto, Japan; March 10–13, 2007.
  36. Sheikh S. Heart failure in Pakistan. A demographic survey [Abstract]. In: *The 10th annual scientific meeting of the Japanese Heart Failure Society*. Tokyo, Japan; October 13–15, 2005.
  37. Hui JM, Sud A, Farrell GC, Bandaru P, Byth K, Kench JG, McCaughan GW, George J. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression. *Gastroenterology* 2003;125:1695–704.
  38. Matsumori A, Ohashi N, Hasegawa K, Sasayama S, Eto T, Imaizumi T, Izumi T, Kawamura K, Kawana M, Kimura A, Kitabatake A, Matsuzaki M, Nagai R, Tanaka H, Hiroe M, Hori M, Inoko H, Seko Y, Sekiguchi M, Shimotohno K, Sugishita Y, Takeda N, Takihara K, Tanaka M, Yokoyama M, et al. Hepatitis C virus infection and heart diseases: a multicenter study in Japan. *Jpn Circ J* 1998;62:389–91.
  39. Ishizaka N, Ishizaka Y, Takahashi E, Tooda E, Hashimoto H, Nagai R, Yamakado M. Association between hepatitis C virus seropositivity, carotid-artery plaque, and intima-media thickening. *Lancet* 2002;359:133–5.
  40. Oyake N, Shimada T, Murakami Y, Ishibashi Y, Satoh H, Suzuki K, Matsumori A, Oda T. Hepatitis C virus infection as a risk factor for increased aortic stiffness and cardiovascular events in dialysis patients. *J Nephrol* 2008;21:345–53.
  41. Mahtab MA, Rahman S, Khan M, Karim MF. Etiologic fraction of hospital-admitted acute hepatitis likely attributable to HEV infection: experience from a tertiary hospital in Bangladesh. *J Health Pop Nutr* 2008.
  42. Saleh A, Matsumori A, Negam H et al. Assessment of cardiac involvement of Hepatitis C virus; tissue Doppler imaging NT-proBNP study. *Journal of the Saudi Heart Association* 2011; 23: 217–23.